U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07730281) titled 'PRA-216 COPD Safety and Biomarker Study' on July 23.
Brief Summary: This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Chronic Obstructive Pulmonary Disease (COPD)
Intervention:
DRUG: PRA-216
biologic
DRUG: Placebo
matching placebo for PRA-216
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Prana Therapies Inc
Disclaimer: Curated by HT Syndication....